Evaluation of Synergetic effect of Celexib & Tadalafil on Erectile Function in Pateint with Erectile Dysfunction

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170417033489N7

Enrollment

Registered

2021-03-16

Start date

2020-10-01

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male erectile dysfunction. Male erectile dysfunction, unspecified

Interventions

Intervention 1: Intervention group:In addition to standard treatment (5 mg daily tadalafil), the group also consumes 200 mg celexib daily for up to 8 weeks. Intervention 2: Control group: One group re

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Existence of erection disorder

Exclusion criteria

Exclusion criteria: Diabetes Heart Failure Kidney failure (GFR disorder) History of mental disorder Simultaneous rheumatic disease Taking other NSAIDs

Design outcomes

Primary

Measure	Time frame
Percentage Of Patient Discharged From The Erectile Dysfunction. Timepoint: 60 Days. Method of measurement: Elimination of erection disorder based on the International Index of Erectile Function Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSalman Soltani

Mashhad University of Medical Sciences

soltanis@mums.ac.ir+98 51 3802 2553

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026